Table 4.
Relationship between tumor- and host-related characteristics and overall survival in 255 patients with endometrial cancer
| Variable | Univariate | Multivariate | |||
|---|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | ||
| Age (years) (≤ 56 vs. > 56) | 2.55 (0.85, 7.67) | 0.0960 | |||
| Histology (endometrioid vs. others) | 12.868 (4.13, 40.02) | < 0.0001 | |||
| Histologic grade (G1 vs. G2-G3) | 69.88 (0.94, 5173.32) | 0.0531 | |||
| FIGO stage (I-II vs. III-IV) | 45.27 (10.00, 204.82) | <0.0001 | 18.67 (4.08, 85.50) | < 0.0001 | |
| LVSI (absent vs. present) | 16.86 (4.70, 60.49) | < 0.0001 | |||
| CA-125 (unit/mL) (≤ 48.1 vs. > 48.1) | 6.76 (2.23, 20.51) | < 0.0001 | |||
| Albumin (g/dL) (≤ 4.4 vs. > 4.4) | 0.22 (0.05, 0.97) | 0.0460 | |||
| WBC (per µL) (≤ 5410 vs. > 5410) | 3.52 (0.46, 27.04) | 0.2260 | |||
| ANC (per µL) (≤ 3665.1 vs. > 3665.1) | 2.47(0.69, 8.85) | 0.1663 | |||
| ALC (per µL) (≤1526.9 vs. >1526.9) | 0.26 (0.09,0.74) | 0.0117 | |||
| AMC (per µL) (≤ 528.4 vs. > 528.4) | 4.86 (1.65, 13.32) | 0.0042 | |||
| Hemoglobin (g/dL) (≤11.7 vs. >11.7) | 0.14 (0.04, 0.44) | < 0.0001 | |||
| MCV (fL) (≤ 90 vs. > 90) | 3.01 (0.99, 9.13) | 0.0513 | |||
| Platelet (x 103/µL) (≤204 vs. >204) | 0.32 (0.09, 1.07) | 0.0638 | |||
| NLR (≤ 2.44 vs. > 2.44) | 3.47 (1.20, 10.05) | 0.0217 | |||
| PLR (≤ 190.78 vs. > 190.78) | 2.89 (1.00, 8.38) | 0.0497 | |||
| LMR (≤ 3.28 vs. > 3.28) | 0.02 (0.01, 0.55) | < 0.0001 | 0.07 (0.02, 0.24) | < 0.0001 | |
HRs were obtained from Cox's proportional hazard model.
HR, hazard ratio; CI, confidence interval; FIGO, International Federation of Gynecology and Obstetrics; LVSI, lymphovascular space invasion;CA-125, cancer antigen 125; WBC, white blood cell; ANC, absolute neutrophil count; ALC, absolute lymphocyte count; AMC, absolute monocyte count; NLR, neutrophil-lymphocyte ratio; PLR, platelet-lymphocyte ratio; LMR, lymphocyte-monocyte ratio